Tholfsen Lena K, Larsen Jan P, Schulz Jörn, Tysnes Ole-Bjørn, Gjerstad Michaela D
From the Norwegian Centre for Movement Disorders (L.K.T., J.S., M.D.G.) and Department of Neurology (L.K.T., M.D.G.), Stavanger University Hospital; Network for Medical Sciences (J.P.L.), Faculty of Social Sciences, University of Stavanger; and Department of Neurology (O.-B.T.), Haukeland University Hospital, Bergen, Norway.
Neurology. 2017 Jan 24;88(4):352-358. doi: 10.1212/WNL.0000000000003540. Epub 2016 Dec 16.
To examine the development of factors associated with insomnia in a cohort of originally drug-naive patients with incident Parkinson disease (PD) during the first 5 years after diagnosis.
One hundred eighty-two drug-naive patients with PD derived from a population-based incident cohort and 202 control participants were assessed for insomnia before treatment initiation and were repeatedly examined after 1, 3, and 5 years. Insomnia was diagnosed according to the Stavanger Sleepiness Questionnaire. The Parkinson's Disease Sleep Scale was used to differentiate sleep initiation problems from problems of sleep maintenance. Generalized estimating equation models were applied for statistical measures.
The prevalence of insomnia in general was not higher in patients with PD compared to controls at the 5-year follow-up. There were changes in the prevalence of the different insomnia subtypes over the 5-year follow-up. The prevalence of solitary problems in sleep maintenance increased from 31% (n = 18) in the drug-naive patients at baseline to 49% (n = 29) after 1 year and were associated with the use of dopamine agonists and higher Montgomery-Åsberg Depression Rating Scale scores. The prevalence of solitary sleep initiation problems decreased continuously from 21% (n = 12) at baseline to 7.4% (n = 4) after 5 years; these were associated with less daytime sleepiness.
The prevalence rates of the different insomnia subtypes changed notably in patients with early PD. The frequency of sleep maintenance problems increased, and these problems were associated with dopamine agonist use and depressive symptoms, while the total number of patients with insomnia remained stable. Our findings reflect the need for early individual assessments of insomnia subtypes and raise the possibility of intervention to reduce these symptoms in patients with early PD.
研究初发未用药的帕金森病(PD)患者队列在诊断后的前5年中与失眠相关因素的发展情况。
对182例来自基于人群的初发队列的未用药PD患者和202名对照参与者在开始治疗前进行失眠评估,并在1年、3年和5年后进行重复检查。根据斯塔万格嗜睡问卷诊断失眠。使用帕金森病睡眠量表区分入睡问题和睡眠维持问题。采用广义估计方程模型进行统计分析。
在5年随访中,PD患者总体失眠患病率与对照组相比并不更高。在5年随访期间,不同失眠亚型的患病率有所变化。单纯睡眠维持问题的患病率从基线时未用药患者的31%(n = 18)增加到1年后的49%(n = 29),并与多巴胺激动剂的使用和较高的蒙哥马利-阿斯伯格抑郁量表评分相关。单纯入睡问题的患病率从基线时的21%(n = 12)持续下降到5年后的7.4%(n = 4);这些问题与白天嗜睡较少有关。
早期PD患者不同失眠亚型的患病率有显著变化。睡眠维持问题的频率增加,且这些问题与多巴胺激动剂的使用和抑郁症状相关,而失眠患者总数保持稳定。我们的研究结果反映了对失眠亚型进行早期个体评估的必要性,并提出了干预以减轻早期PD患者这些症状的可能性。